Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609203 · ClinicalTrials.gov registry record
Improving Self-Efficacy, Resolving Inflammaging Allo HSCT Survivors in Personal Training
A clinical trial, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- 25
- Enrollment target
NCT03609203: Completed study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT03609203 is a clinical trial that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03609203 has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This protocol is a pilot study of a personalized and supervised 10-week strength training program to improve self-efficacy and resolve biomarkers of inflammaging in a cohort of allogeneic hematopoietic transplant (HCT) long-term survivors versus healthy controls.
Primary Outcome
To quantify the changes in self-reported outcomes of self-efficacy after ten weeks of strength training in patients compared to controls.
Interventions
- OTHER 10 Weeks of Strength Trailing
- OTHER Group Nutrition Discussion: week 1, week 5 and week 10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2021-03-31 |
What the finished NCT03609203 record still lists
NCT03609203 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which 10 Weeks of Strength Trailing is the first listed.
NCT03609203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03609203 about?
NCT03609203 is a clinical study titled "Improving Self-Efficacy, Resolving Inflammaging Allo HSCT Survivors in Personal Training". This protocol is a pilot study of a personalized and supervised 10-week strength training program to improve self-efficacy and resolve biomarkers of inflammaging in a cohort of allogeneic hematopoietic transplant (HCT) long-term survivors versus healthy controls.
What is the current status of trial NCT03609203?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2018-09-10. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03609203?
The interventions under investigation include: 10 Weeks of Strength Trailing (OTHER), Group Nutrition Discussion: week 1, week 5 and week 10 (OTHER).
Who is sponsoring clinical trial NCT03609203?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI